Formulation Considerations for Intranasal Peptide Delivery
pH, osmolarity, preservatives, and permeation enhancers for intranasal peptide formulations.
A technical review of formulation parameters affecting intranasal peptide stability, absorption, and tolerability.
Formulating peptides for intranasal delivery requires careful consideration of multiple physicochemical parameters that affect stability, absorption, and mucosal tolerability. This article reviews the key formulation considerations for intranasal peptide preparations.
pH Optimization
The pH of intranasal formulations significantly affects both peptide stability and absorption:
- β’Physiological nasal pH β 5.5-6.5; formulations should match this range for comfort
- β’Peptide stability β each peptide has an optimal pH for maximum stability; formulation pH must balance stability and tolerability
- β’Ionization state β pH affects the charge state of ionizable amino acid residues, influencing membrane permeability
Formulations outside the pH 4.5-7.4 range may cause nasal irritation or mucosal damage with repeated use.
Osmolarity
Nasal mucosa is sensitive to tonicity:
- β’Isotonic (280-290 mOsm/L) β optimal for mucosal comfort and peptide stability
- β’Hypertonic (>300 mOsm/L) β can draw water from mucosal tissue, causing irritation
- β’Hypotonic (<260 mOsm/L) β may cause cellular swelling and discomfort
Sodium chloride is the most common osmolarity agent, with mannitol and dextrose as alternatives.
Permeation Enhancers
Several classes of permeation enhancers can improve intranasal peptide absorption:
- β’Chitosan β a cationic polysaccharide that transiently opens tight junctions
- β’Cyclodextrins β form inclusion complexes with peptides, improving solubility
- β’Bile salts β disrupt lipid bilayers (use with caution due to mucosal irritation)
- β’Phospholipids β enhance membrane permeability
Permeation enhancers must be used judiciously, as they can cause reversible or irreversible mucosal damage at higher concentrations.
Preservatives and Stability
Multi-dose intranasal formulations require preservatives to prevent microbial contamination:
- β’Benzalkonium chloride (BAK) β common but may cause mucosal irritation with long-term use
- β’Benzyl alcohol β milder preservative, suitable for most peptide formulations
- β’Single-dose β eliminates preservative need entirely
Semax and Selank are typically supplied as sterile aqueous solutions for intranasal use, with formulation considerations including pH adjustment and preservative selection.
Device Considerations
Intranasal delivery devices affect dosing accuracy and deposition patterns:
- β’Metered-dose spray pumps β consistent dose delivery, particle size 20-100 ΞΌm
- β’Dropper bottles β less precise but simpler
- β’Nasal drops β suitable for small volumes
Particle size affects deposition location: larger droplets (>50 ΞΌm) deposit in the anterior nasal cavity, while smaller particles may reach the olfactory region.
Formulation Stability
Peptide stability in intranasal formulations depends on:
- β’Temperature (refrigeration extends shelf life)
- β’Light protection (amber containers)
- β’Oxidation prevention (nitrogen overlay, antioxidants)
- β’Aggregation prevention (avoidance of mechanical stress)
Research Use Only. Not for human consumption. All referenced compounds are intended for laboratory research purposes only.
Keywords
Research Goals
(1)For research use only. Not medical advice.